Market capitalization | $79.39m |
Enterprise Value | $72.63m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 38.63 |
P/S ratio (TTM) P/S ratio | 42.23 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $1.88m |
EBIT (operating result TTM) EBIT | $-17.05m |
EPS (TTM) EPS | $-0.40 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast BeyondSpring Inc.:
1 Analyst has issued a forecast BeyondSpring Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 1.88 1.88 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -17 -17 |
74%
74%
|
Net Profit | -16 -16 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
Head office | Cayman Islands |
CEO | Lan Huang |
Employees | 35 |
Founded | 2010 |
Website | www.beyondspringpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.